Jamieson 10 billion
Lacticaseibacillus rhamnosus UALr-18
Strain code: UALr-18
CFU: 10 billion CFU
View product →Lactobacillus rhamnosus shows some evidence of benefit for certain skin problems such as atopic dermatitis and possibly pediatric atopic eczema, but evidence for acne vulgaris is mixed and not conclusive.
High-quality randomized controlled trials and meta-analyses indicate that Lactobacillus rhamnosus may reduce symptoms of atopic dermatitis in children, with significant improvements in SCORAD scores after 8 weeks of treatment (PMID: 26733351). For pediatric atopic dermatitis prevention, Lactobacillus rhamnosus combined with other probiotics probably reduces risk based on moderate-quality evidence (PMID: 33811784). However, for acne vulgaris, evidence is mixed: one RCT showed improved outcomes when probiotics were combined with doxycycline (PMID: 39410868), and another trial with Lacticaseibacillus rhamnosus showed some improvement in non-inflammatory lesions (PMID: 38751177). Conversely, a meta-analysis found no significant benefit of Lactobacillus-based probiotics on acne lesion counts compared to placebo or benzoyl peroxide (PMID: 41853869). For eczema treatment, probiotics including Lactobacillus strains probably make little or no difference in patient-rated symptoms and quality of life (PMID: 30480774). Safety profiles across studies were generally good with no significant adverse effects reported. Limitations include heterogeneity of probiotic strains, doses, and study designs, as well as some low to moderate quality evidence and small sample sizes in some trials.
Evidence strongest for atopic dermatitis in children; strain-specific effects important; less clear benefit for acne.
May be beneficial for acne vulgaris but evidence is limited to one RCT; combined with Arthrospira platensis in study.
Probiotics including Lactobacillus rhamnosus were generally safe and well tolerated across studies with no significant increase in adverse events reported. Minor gastrointestinal symptoms were occasionally noted but not significantly different from placebo.
Heterogeneity in probiotic strains, doses, and treatment durations; some studies combined Lactobacillus rhamnosus with other probiotics or agents; mixed results especially for acne vulgaris; some evidence based on low to moderate quality studies; small sample sizes in some trials; lack of standardization limits generalizability.
These products contain microorganisms identified in the research analysis above.
Lacticaseibacillus rhamnosus UALr-18
Strain code: UALr-18
CFU: 10 billion CFU
View product →
Lacticaseibacillus rhamnosus SD-5218
Strain code: SD-5218
CFU: 100 billion CFU
View product →
Lacticaseibacillus rhamnosus HN001
Strain code: HN001
CFU: 50 Billion CFU
View product →
Lacticaseibacillus rhamnosus Lr-32
Strain code: Lr-32
CFU: 25 Billion CFU
View product →
Lacticaseibacillus rhamnosus GG
Strain code: ATCC 53103
CFU: 15 billion CFU
View product →
Lacticaseibacillus rhamnosus
Probiotics.info is an educational and research platform. Its content does not constitute medical advice.
By continuing, you acknowledge our policies and agree to our Terms of Use.
Necessary cookies keep the website working. You can also allow optional cookies for analytics and referral tracking.
You can change your cookie preferences later.